Organization
Wexner Medical Center and The James Cancer Hospital, Ohio State University, Columbus, OH
1 abstract
Abstract
UPGRADE-A: Phase 1 expansion trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi) in combination with carboplatin in patients with high-grade serous ovarian cancer (HGSOC).Org: Wexner Medical Center and The James Cancer Hospital, Ohio State University, Columbus, OH, Memorial Sloan Kettering Cancer Center, New York, NY, USA, START Midwest, Grand Rapids, MI, Willamette Valley Cancer Institute, Eugene, OR, Arizona Oncology Associates, Tucson, AZ,